CO6362024A2 - Anticuerpos humanos de alta afinidad para el receptor il-4 humano - Google Patents

Anticuerpos humanos de alta afinidad para el receptor il-4 humano

Info

Publication number
CO6362024A2
CO6362024A2 CO11051317A CO11051317A CO6362024A2 CO 6362024 A2 CO6362024 A2 CO 6362024A2 CO 11051317 A CO11051317 A CO 11051317A CO 11051317 A CO11051317 A CO 11051317A CO 6362024 A2 CO6362024 A2 CO 6362024A2
Authority
CO
Colombia
Prior art keywords
antibody
human
antigen
binds
fragment
Prior art date
Application number
CO11051317A
Other languages
English (en)
Spanish (es)
Inventor
Joel H Martin
Tammy Huang
Nicholas Papadopoulos
Jeanette Fairhurst
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41600767&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6362024(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CO6362024A2 publication Critical patent/CO6362024A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
CO11051317A 2008-10-29 2011-04-27 Anticuerpos humanos de alta afinidad para el receptor il-4 humano CO6362024A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/260,307 US7608693B2 (en) 2006-10-02 2008-10-29 High affinity human antibodies to human IL-4 receptor

Publications (1)

Publication Number Publication Date
CO6362024A2 true CO6362024A2 (es) 2012-01-20

Family

ID=41600767

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11051317A CO6362024A2 (es) 2008-10-29 2011-04-27 Anticuerpos humanos de alta afinidad para el receptor il-4 humano

Country Status (47)

Country Link
US (7) US7608693B2 (2)
EP (7) EP2511300A3 (2)
JP (8) JP5291802B2 (2)
KR (1) KR101599706B1 (2)
CN (3) CN103739711B (2)
AR (1) AR073978A1 (2)
AU (1) AU2009311496B9 (2)
BR (1) BRPI0919853B8 (2)
CA (1) CA2737044C (2)
CL (1) CL2009002004A1 (2)
CO (1) CO6362024A2 (2)
CR (1) CR20110148A (2)
CY (3) CY1114123T1 (2)
DK (3) DK3064511T3 (2)
EC (1) ECSP11011010A (2)
ES (4) ES2404206T3 (2)
FI (1) FI3715372T3 (2)
FR (1) FR18C1011I2 (2)
HN (1) HN2011001210A (2)
HR (3) HRP20130467T1 (2)
HU (3) HUE066473T2 (2)
IL (1) IL211726A (2)
JO (1) JO2865B1 (2)
LT (3) LT3715372T (2)
LU (1) LUC00059I2 (2)
MA (1) MA32802B1 (2)
MX (3) MX2011003346A (2)
MY (1) MY152448A (2)
NI (1) NI201100064A (2)
NL (1) NL300922I2 (2)
NO (2) NO2018009I2 (2)
NZ (2) NZ591922A (2)
PA (1) PA8847001A1 (2)
PE (1) PE20100738A1 (2)
PH (1) PH12014500462A1 (2)
PL (4) PL3351560T3 (2)
PT (4) PT3351560T (2)
RS (3) RS57522B1 (2)
RU (2) RU2539774C3 (2)
SI (3) SI3064511T1 (2)
SM (2) SMT201800362T1 (2)
SV (1) SV2011003880A (2)
TW (3) TWI538686B (2)
UA (1) UA102122C2 (2)
UY (1) UY32213A (2)
WO (1) WO2010053751A1 (2)
ZA (1) ZA201101867B (2)

Families Citing this family (172)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2564432A1 (en) * 2004-04-27 2005-11-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human anti-amyloid .beta. peptide antibody and fragment of said antibody
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
MY149079A (en) 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
SMT202600080T1 (it) 2010-02-08 2026-03-09 Regeneron Pharma Topo con catena leggera comune
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
UA111731C2 (uk) * 2010-10-06 2016-06-10 Рідженерон Фармасьютікалз, Інк. Стабілізована композиція, яка містить антитіло до рецептора інтерлейкіну-4 (іl-4r), варіанти
NZ609557A (en) * 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
SG192117A1 (en) 2011-01-28 2013-08-30 Sanofi Sa Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
HUE047278T2 (hu) 2011-08-05 2020-04-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
HUE069234T2 (hu) 2011-09-16 2025-02-28 Regeneron Pharma Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
TW201333034A (zh) 2011-12-22 2013-08-16 Astellas Pharma Inc 新穎抗人類ｃｔｇｆ抗體
EP2825036B1 (en) 2012-03-16 2018-05-02 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
EP3539374A1 (en) 2012-03-16 2019-09-18 Regeneron Pharmaceuticals, Inc. Non-human animals expressing ph-sensitive immunoglobulin sequences
TWI721272B (zh) * 2012-08-21 2021-03-11 法商賽諾菲生物技術公司 投與il-4r拮抗劑以治療或預防氣喘之方法
US9574004B2 (en) * 2012-08-21 2017-02-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
PT2892927T (pt) * 2012-09-07 2018-08-02 Regeneron Pharma Métodos para tratamento da dermatite atópica por administração de um antagonista de il-4r
PT3889181T (pt) * 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
CN111437387B (zh) 2013-06-21 2024-10-01 赛诺菲生物技术公司 通过施用il-4r拮抗剂治疗鼻息肉症的方法
TWI707694B (zh) * 2013-06-21 2020-10-21 法商賽諾菲生物技術公司 Ｉｌ-４ｒ拮抗劑用於製造治療鼻息肉症的藥物之用途
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
CN118105480A (zh) 2013-11-12 2024-05-31 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
DE112014005975T5 (de) * 2013-12-17 2016-09-15 Kymab Limited Menschliche Ziele
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US10167333B2 (en) * 2014-01-16 2019-01-01 Mario Umberto Francesco Mondelli Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
IL247290B (en) * 2014-02-21 2021-06-30 Sanofi Biotechnology Methods of treating or preventing asthma by adding an il-4r antagonist
WO2015130975A1 (en) * 2014-02-28 2015-09-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
NO2785538T3 (2) 2014-05-07 2018-08-04
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
AU2015346150B2 (en) 2014-11-14 2021-08-19 Regeneron Pharmaceuticals, Inc. Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
CA2980087A1 (en) 2015-04-02 2016-10-06 Intervet International B.V. Antibodies to canine interleukin-4 receptor alpha
TWI870789B (zh) * 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
AU2017220184B2 (en) 2016-02-19 2024-04-18 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist
CN113372446A (zh) 2016-06-08 2021-09-10 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
HUE067888T2 (hu) 2016-09-01 2024-11-28 Regeneron Pharma Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
EP4345110A3 (en) 2016-09-22 2024-06-12 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
EP3548514A1 (en) 2016-11-29 2019-10-09 Regeneron Pharmaceuticals, Inc. Methods of treating prlr positive breast cancer
TWI784988B (zh) * 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
MX2019012171A (es) 2017-04-13 2019-11-25 Regeneron Pharma Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1.
BR112020000127A2 (pt) 2017-07-06 2020-07-07 Regeneron Pharmaceuticals, Inc. método para selecionar um hidrolisado de soja, e, glicoproteína
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
CA3079946A1 (en) 2017-10-30 2019-05-09 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
MX2020006639A (es) 2017-12-22 2020-09-14 Regeneron Pharma Sistema y metodo para caracterizar las impurezas de un producto farmaceutico.
BR112020013336A2 (pt) 2018-01-31 2020-12-01 Regeneron Pharmaceuticals, Inc. produto farmacêutico proteico, métodos para caracterizar as impurezas do produto farmacêutico proteico de alto peso molecular intermediário, para produção de um anticorpo, e para caracterizar as impurezas de fármaco com variação de carga, anticorpo, e, sistema para caracterizar impurezas de fármaco de alto peso molecular intermediário.
RU2758092C1 (ru) * 2018-02-01 2021-10-26 Бэйцзин Кавин Текнолоджи Шеа-Холдинг Ко., Лтд. АНТИТЕЛО К IL-4Rα И ЕГО ПРИМЕНЕНИЕ
CN113150146B (zh) * 2018-02-01 2022-07-12 北京凯因科技股份有限公司 IL-4Rα抗体及其用途
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
WO2019168774A1 (en) 2018-02-28 2019-09-06 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
HUE065344T2 (hu) 2018-03-19 2024-05-28 Regeneron Pharma Mikrochip kapilláris elektroforézis assay-k és reagensek
CN112512571B (zh) * 2018-03-22 2025-02-07 表面肿瘤学有限责任公司 抗il-27抗体及其用途
CN108373505B (zh) 2018-04-20 2019-08-20 北京智仁美博生物科技有限公司 抗il-4r抗体及其用途
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
US11292847B2 (en) 2018-05-13 2022-04-05 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R inhibitor
CN110540590B (zh) * 2018-05-29 2023-08-18 康诺亚生物医药科技（成都）有限公司 一种自免疫抑制物的开发和应用
AR115730A1 (es) * 2018-07-10 2021-02-17 Regeneron Pharma Modificación de moléculas de unión para minimizar interacciones pre-existentes
US12162944B2 (en) 2018-08-24 2024-12-10 Jiangsu Hengrui Medicine Co., Ltd. Human IL-4R binding antibody, antigen binding fragment thereof, and medical use thereof
CN119264211A (zh) 2018-08-27 2025-01-07 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
JP7511542B2 (ja) 2018-08-30 2024-07-05 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タンパク質複合体を特徴づけるための方法
CN110872349A (zh) 2018-09-04 2020-03-10 三生国健药业（上海）股份有限公司 结合人il-4r的抗体、其制备方法和用途
KR102330596B1 (ko) * 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
US11312778B2 (en) 2018-11-21 2022-04-26 Brian C. Machler Method for treating allergic contact dermatitis
CN110746507B (zh) * 2018-12-25 2020-06-26 江苏荃信生物医药有限公司 抗人白介素4受体α单克隆抗体及其应用
WO2020150491A1 (en) 2019-01-16 2020-07-23 Regeneron Pharmaceuticals, Inc. Methods for characterizing disulfide bonds
MX2021010560A (es) 2019-03-06 2021-11-12 Regeneron Pharma Inhibidores de la via il-4/il-13 para una eficacia aumentada en el tratamiento de cancer.
CA3132587A1 (en) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
WO2020231992A1 (en) 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
CN111592597B (zh) 2019-05-29 2022-04-26 山东博安生物技术股份有限公司 白介素4受体(il-4r)结合蛋白及其用途
CN110343666B (zh) * 2019-07-10 2023-05-30 通化东宝药业股份有限公司 一种cho细胞培养的补料培养基及其制备方法和应用
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
WO2021026205A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
WO2021061790A1 (en) 2019-09-24 2021-04-01 Regeneron Pharmaceuticals, Inc. Systems and methods for chromatography use and regeneration
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN111825766B (zh) * 2019-10-31 2021-05-11 上海洛启生物医药技术有限公司 抗il-4r单域抗体及其应用
CA3158119A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
EP3992974A1 (en) 2020-11-02 2022-05-04 Sanofi Biotechnology Methods for treating digitally-identified il-4/il-13 related disorders
IL293487A (en) 2019-12-09 2022-08-01 Sanofi Biotechnology Methods for the treatment of digitally identified il-4/il-13-related disorders
CN121108343A (zh) 2019-12-20 2025-12-12 英特维特国际股份有限公司 犬白介素-4受体α抗体
CN115398236B (zh) 2020-01-21 2024-06-11 瑞泽恩制药公司 用于糖基化的蛋白质的电泳的去糖基化方法
CA3169959A1 (en) 2020-02-21 2021-08-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition containing anti-il-4r antibody and use thereof
BR112022017174A2 (pt) * 2020-02-27 2022-10-18 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, nucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica e métodos de tratamento de uma doença alérgica e de um tumor
MX2022011730A (es) 2020-03-27 2022-10-13 Regeneron Pharma Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r.
CN113549151A (zh) * 2020-04-24 2021-10-26 苏州康乃德生物医药有限公司 与人IL-4Rα中特定表位结合的抗体及其应用
EP4153300A1 (en) 2020-05-22 2023-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
WO2022047108A1 (en) 2020-08-31 2022-03-03 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
JP2023544406A (ja) 2020-10-05 2023-10-23 サノフィ・バイオテクノロジー Ｉｌ－４ｒアンタゴニストを投与することによって小児対象における喘息を治療するための方法
WO2022115588A1 (en) 2020-11-25 2022-06-02 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
KR20230121854A (ko) 2020-12-17 2023-08-21 리제너론 파아마슈티컬스, 인크. 단백질-캡슐화 마이크로겔의 제작
WO2022135441A1 (zh) 2020-12-22 2022-06-30 江苏恒瑞医药股份有限公司 抗il-4r抗体或其抗原结合片段的复合物及医药用途
EP4274609A1 (en) 2021-01-08 2023-11-15 Regeneron Pharmaceuticals, Inc. Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist
MX2023008527A (es) 2021-01-20 2023-07-28 Regeneron Pharma Metodos para mejorar el valor proteico en cultivo celular.
JP2024512299A (ja) 2021-03-03 2024-03-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド タンパク質の粘度を定量及び変更するためのシステム及び方法
AU2022243005A1 (en) 2021-03-26 2023-10-05 Regeneron Pharmaceuticals, Inc. Methods and systems for developing mixing protocols
BR112023024984A2 (pt) 2021-06-01 2024-02-20 Regeneron Pharma Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
IL310362A (en) 2021-07-26 2024-03-01 Sanofi Biotechnology Methods for the treatment of chronic spontaneous urticaria by administration of an IL-4R antagonist
TWI876192B (zh) * 2021-08-05 2025-03-11 美商美國禮來大藥廠 人類介白素-4受體α抗體
US20230235069A1 (en) 2021-08-10 2023-07-27 Kymab Limited Treatment of atopic dermatitis
IL310962A (en) 2021-08-23 2024-04-01 Regeneron Pharma Methods for treating atopic dermatitis by administering an IL-4R antagonist
TW202313692A (zh) * 2021-08-26 2023-04-01 大陸商正大天晴藥業集團股份有限公司 抗ｉｌ４ｒ抗體的藥物組成物及其用途
US20230077710A1 (en) 2021-09-08 2023-03-16 Regeneron Pharmaceuticals, Inc. HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS
CA3232463A1 (en) 2021-09-20 2023-03-23 Philip Mellors Methods of controlling antibody heterogeneity
KR20240067064A (ko) 2021-09-30 2024-05-16 리제너론 파마슈티칼스 인코포레이티드 레티쿨로칼빈-3[rcn3] 변이체 및 인터류킨-4 수용체 알파[il4r] 길항제를 이용한 천식의 치료
CA3230984A1 (en) 2021-10-07 2023-04-13 Ross BROWNE Systems and methods of ph modeling and control
WO2023059803A1 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Ph meter calibration and correction
IL312187A (en) 2021-10-20 2024-06-01 Regeneron Pharma Methods for treating prurigo nodularis by administering an IL-4R antagonist
TW202330104A (zh) 2021-10-26 2023-08-01 美商再生元醫藥公司 用於產生實驗室用水及分配不同溫度之實驗室用水的系統及方法
WO2023085978A1 (en) * 2021-11-11 2023-05-19 Joint Stock Company «Biocad» Monoclonal antibody or antigen-binding fragment thereof that specifically binds to il-4ra, and use thereof
CA3236201A1 (en) 2021-11-11 2023-05-19 Regeneron Pharmaceuticals, Inc. Treatment of lung disease based upon stratification of polygenic risk score for interleukin 33 (il-33)
US12134656B2 (en) 2021-11-18 2024-11-05 Twist Bioscience Corporation Dickkopf-1 variant antibodies and methods of use
CA3237320A1 (en) 2021-11-30 2023-06-08 Regeneron Pharmaceuticals, Inc. Treatment of lung disease based upon stratification of polygenic score relating to response to a therapeutic agent
US20230220089A1 (en) 2021-12-30 2023-07-13 Regeneron Pharmaceuticals, Inc. Methods for attenuating atopic march by administering an il-4/il-13 antagonist
MX2024009080A (es) 2022-01-29 2024-07-30 Shanghai Shengdi Pharmaceutical Co Ltd Conjugado farmacologico de glucocorticoide.
CN119301236A (zh) 2022-03-02 2025-01-10 瑞泽恩制药公司 用于抗体生产的生物反应器
KR20240164561A (ko) 2022-03-18 2024-11-19 리제너론 파아마슈티컬스, 인크. 폴리펩타이드 변종을 분석하기 위한 방법 및 시스템
WO2023191665A1 (en) * 2022-03-31 2023-10-05 Milaboratory, Limited Liability Company ANTIBODIES TO HUMAN IL-4Rα HAVING REDUCED IMMUNOGENICITY AND APPLICATION THEREOF
KR20250037491A (ko) 2022-07-08 2025-03-17 리제너론 파아마슈티컬스, 인크. Il-4r 길항제 투여에 의한 소아 호산구성 식도염을 치료하는 방법
CN120091829A (zh) 2022-08-29 2025-06-03 赛诺菲生物技术公司 通过施用il-4r拮抗剂治疗慢性诱导性寒冷性荨麻疹的方法
KR20240038841A (ko) 2022-09-16 2024-03-26 연세대학교 산학협력단 신규한 인간 인터류킨-4 수용체 결합 나노바디 및 이의 용도
CN120187754A (zh) 2022-11-01 2025-06-20 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗手足皮炎的方法
JP2025541690A (ja) 2022-11-23 2025-12-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒアンタゴニストを投与することによる、骨成長を改善するための方法
TW202435942A (zh) 2022-12-16 2024-09-16 美商里珍納龍藥品有限公司 評估層析管柱完整性的方法及系統
US20240245779A1 (en) 2023-01-25 2024-07-25 Regeneron Pharmaceuticals, Inc. Methods of modeling liquid protein composition stability
EP4655595A1 (en) 2023-01-25 2025-12-03 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
WO2024163708A1 (en) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Asymmetrical flow field-flow fractionation with mass spectrometry for biomacromolecule analysis
AU2024221322A1 (en) * 2023-02-17 2025-07-03 Apogee Therapeutics, Inc. Antibodies that bind interleukin 4 receptor alpha and methods of use
EP4669963A2 (en) 2023-02-22 2025-12-31 Regeneron Pharmaceuticals, Inc. SYSTEM FITNESS PARAMETERS AND COLUMN AGING
AU2024241290A1 (en) 2023-03-22 2025-11-06 Regeneron Pharmaceuticals, Inc. Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist
EP4688142A1 (en) 2023-03-27 2026-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic gastroenteritis by administering an il-4r antagonist
EP4687971A1 (en) 2023-03-30 2026-02-11 Sandoz Ag Stable composition comprising a high protein concentration
US20240366471A1 (en) 2023-05-01 2024-11-07 Regeneron Pharmaceuticals, Inc. Multidose antibody drug products using phenol or benzyl alcohol
KR20240170605A (ko) * 2023-05-23 2024-12-04 연세대학교 산학협력단 신규한 인간 인터류킨-4 수용체 결합 나노바디 및 이를 포함하는 비강 분무 제형
CN121568722A (zh) 2023-07-28 2026-02-24 江苏恒瑞医药股份有限公司 一种含有糖皮质激素的抗体药物偶联物的药物组合物
WO2025054406A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
US20250095773A1 (en) 2023-09-18 2025-03-20 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
US20250109905A1 (en) 2023-09-29 2025-04-03 Regeneron Pharmaceuticals, Inc. Lyophilization using controlled nucleation
WO2025075970A1 (en) 2023-10-02 2025-04-10 Regeneron Pharmaceuticals, Inc. Drug delivery device safety system
US20250129117A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
US20250145662A1 (en) 2023-11-02 2025-05-08 Regeneron Pharmaceuticals, Inc. Methods for reducing lipase activity using stress
US20250179207A1 (en) 2023-11-30 2025-06-05 Genzyme Corporation Methods for treating digitally-identified cd20-related disorders
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法
CN117924490B (zh) * 2023-12-22 2024-10-22 华润生物医药有限公司 抗il-4r抗体及其用途
WO2025166234A1 (en) * 2024-01-31 2025-08-07 Apogee Therapeutics, Inc. Methods of administering antibodies that bind interleukin 4 receptor alpha
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
TW202602489A (zh) 2024-03-15 2026-01-16 美商再生元醫藥公司 作為經穩定的蛋白質調配物之賦形劑的聚山梨醇酯及聚氧乙烯山梨糖醇酐
EP4623903A1 (en) 2024-03-28 2025-10-01 Fresenius Kabi Deutschland GmbH Pharmaceutical composition comprising dupilumab
US20250388685A1 (en) 2024-04-15 2025-12-25 Sanofi Biotechnology Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist
US20260008857A1 (en) * 2024-06-13 2026-01-08 Flagship Pioneering Innovations Vi, Llc Antigen Binding Molecules Targeting Interleukine-4 Receptor Subunit Alpha (IL-4Ra)
WO2025259840A1 (en) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and systems for scaled chromatography
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease
WO2026025028A1 (en) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Methods of making ultra-high concentrated protein formulations using lyophilization
WO2026055687A1 (en) 2024-09-09 2026-03-12 Regeneron Pharmaceuticals, Inc. Methods for treating bullous pemphigoid by administering an il-4r antagonist
WO2026059949A1 (en) 2024-09-10 2026-03-19 Sanofi Biotechnology Methods for treating chronic pruritus of unknown origin (cpuo) by administering an il-4r antagonist
WO2026060350A1 (en) 2024-09-13 2026-03-19 Regeneron Pharmaceuticals, Inc. Methods of improving photo stability and controlling formation of hmw species in biologic formulations, and biologic formulations produced by the methods
WO2026076201A2 (en) 2024-10-03 2026-04-09 Regeneron Pharmaceuticals, Inc. Systems and methods for producing therapeutic proteins using single pass tangential flow filtration for in-line concentration and volume reduction of production pools
WO2026080597A1 (en) 2024-10-08 2026-04-16 Regeneron Pharmaceuticals, Inc. Sustained delivery of biologics and non-aqueous manufacture of same

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041381A (en) * 1986-07-03 1991-08-20 Schering Corporation Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
GB8808015D0 (en) * 1988-04-06 1988-05-05 Ritter M A Chemical compounds
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
JPH06510750A (ja) * 1991-05-03 1994-12-01 セラジェン　インク 炎症性関節炎治療を目的としてインタ−ロイキン受容体を標的にした分子
CA2130436C (en) * 1992-02-19 2001-04-10 John S. Abrams Cloning and expression of humanized monoclonal antibodies against human interleukin-4
JP3315427B2 (ja) 1992-03-05 2002-08-19 大日本除蟲菊株式会社 皮膚炎治療剤
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5714146A (en) * 1992-08-26 1998-02-03 Board Of Regents Of The University Of Washington IL-4 bone therapy
EP0604693A1 (en) 1992-12-29 1994-07-06 Schering-Plough Monoclonal antibodies against the human interleukin-4 receptor and hybridomas producing the same
RU2162711C2 (ru) * 1993-09-07 2001-02-10 Смитклайн Бичам Корпорейшн Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
US6387632B2 (en) * 1998-06-11 2002-05-14 Hitachi, Ltd. Polynucleotide separation method and apparatus therefor
ATE326239T1 (de) 1998-09-18 2006-06-15 Dynavax Tech Corp Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren
US6787637B1 (en) 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
DK2990420T3 (en) 2000-05-26 2017-04-03 Immunex Corp USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
EP1304115B1 (en) 2000-07-26 2007-09-12 Hououdou Co. Ltd. Antipruritic compositions and compositions promoting wound healing
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
BR0116415A (pt) 2000-12-22 2003-12-30 Nestle Sa Indução de toler ncia
US20030103938A1 (en) 2001-05-09 2003-06-05 Alk-Abello A/S Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio
US20050031609A1 (en) 2001-05-11 2005-02-10 Thomas Hultsch Compositions for use in treating ige-associated disorders
CA2447795A1 (en) 2001-05-23 2002-11-28 Duotol Ab Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof
AR037456A1 (es) 2001-11-30 2004-11-10 Biogen Inc Anticuerpos contra proteinas quimiotacticas monocitarias
PT1527100E (pt) 2002-03-29 2009-08-25 Schering Corp Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2004070011A2 (en) 2003-02-01 2004-08-19 Tanox, Inc. HIGH AFFINITY ANTI-HUMAN IgE ANTIBODIES
US7923209B2 (en) 2003-03-14 2011-04-12 Anergis, S.A. Allergen peptide fragments and use thereof
BRPI0416603A (pt) 2003-11-07 2007-01-30 Immunex Corp anticorpo que se liga ao receptor interleucina-4 (il-4) humano
AU2004309373A1 (en) * 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
EP1723173B1 (en) 2004-02-27 2008-05-14 Regeneron Pharmaceuticals, Inc. Il-4/il-13 specific polypeptides and therapeutic uses thereof
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US20090098142A1 (en) 2004-06-09 2009-04-16 Kasaian Marion T Methods and compositions for treating and monitoring treatment of IL-13-associated disorders
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
PE20060560A1 (es) * 2004-08-03 2006-06-27 Novartis Ag Anticuerpos de interleucina-4 humana
JP5234445B2 (ja) 2004-10-05 2013-07-10 源一郎 杣 薬剤
US8030003B2 (en) 2004-12-07 2011-10-04 Children's Hospital Medical Center Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3
TWI306862B (en) 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
EP2441838A3 (en) 2006-01-24 2013-07-10 Domantis Limited Fusion proteins that contain natural junctions
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
JP4221018B2 (ja) 2006-08-31 2009-02-12 トヨタ自動車株式会社 頭部保護エアバッグ装置
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
MY149079A (en) 2006-10-02 2013-07-15 Regeneron Pharma High affinity human antibodies to human il-4 receptor
SI2132230T1 (sl) 2007-03-22 2014-07-31 Genentech, Inc. Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE
EP2022507A1 (en) 2007-08-07 2009-02-11 Universität Hamburg Antibody compositions specific for lgE, lgG4 and lgA epitopes as tools for the design of hypoallergenic molecules for specific immunotherapy
WO2009061819A1 (en) 2007-11-05 2009-05-14 The Regents Of The University Of Colorado Minimally-invasive measurement of esophageal inflammation
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
KR101759457B1 (ko) 2007-12-21 2017-07-31 메디뮨 리미티드 인터루킨-4 수용체 알파(ＩＬ-4Ｒα)에 대한 결합 구성원-173
DE202008006598U1 (de) 2008-04-11 2008-10-02 Alk-Abelló A/S Allergie-Impfstoff-Formulierung zur mucosalen Verabreichung
US20090264392A1 (en) 2008-04-21 2009-10-22 Meritage Pharma, Inc. Treating eosinophilic esophagitis
AU2009322556A1 (en) 2008-12-01 2011-07-21 Children's Hospital Medical Center Methods of determining efficacy of glucocorticoid treatment of eosinophilic esophagitis
US20120088814A1 (en) 2009-03-31 2012-04-12 Isis Pharmaceuticals, Inc. Methods of modulating an immune response to a viral infection
US8497528B2 (en) 2010-05-06 2013-07-30 Taiwan Semiconductor Manufacturing Company, Ltd. Method for fabricating a strained structure
CN107320722A (zh) 2009-09-07 2017-11-07 Dbv技术公司 治疗嗜酸细胞性食管炎的方法
US8993347B2 (en) 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
EP3970726A1 (en) 2010-06-24 2022-03-23 ViroPharma Biologics LLC Methods of treatment for esophageal inflammation
NZ609557A (en) * 2010-10-06 2014-12-24 Regeneron Pharma Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies
RU2453303C1 (ru) 2010-12-23 2012-06-20 Общество с ограниченной ответственностью "ЦитоНИР" (ООО "ЦитоНИР") Фармацевтическая композиция для лечения атопического дерматита
EP2661631A4 (en) 2011-01-06 2014-05-21 Childrens Hosp Medical Center EXPRESSION PROFILES FOR OSSOPHAGEAL CYTOKINE IN EOSINOPHILIAN ESOPHAGITIS
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
US9928344B2 (en) 2011-06-21 2018-03-27 Children's Hospital Medical Center Diagnostic methods of eosinophilic esophagitis
CN103974706A (zh) 2011-10-06 2014-08-06 N·V·努特里奇亚 嗜酸细胞性食管炎的治疗
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
KR20140119777A (ko) 2012-01-31 2014-10-10 제넨테크, 인크. 항-ig-e m1'' 항체 및 그의 사용 방법
WO2013155010A1 (en) 2012-04-09 2013-10-17 Children's Hospital Medical Center Non-invasive biomarkers for eosinophilic esophagitis
US9574004B2 (en) 2012-08-21 2017-02-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
PT3889181T (pt) 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
US10132809B2 (en) 2012-10-10 2018-11-20 Rhote Island Hospital Differential expression of protein markers for the diagnosis and treatment of eosinophilic esophagitis
WO2014122143A1 (en) 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
TWI633891B (zh) 2013-06-04 2018-09-01 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法
CN111437387B (zh) 2013-06-21 2024-10-01 赛诺菲生物技术公司 通过施用il-4r拮抗剂治疗鼻息肉症的方法
TWI682781B (zh) 2013-07-11 2020-01-21 美商再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
RU2552929C1 (ru) 2013-11-14 2015-06-10 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
WO2015130975A1 (en) 2014-02-28 2015-09-03 Regeneron Pharmaceuticals, Inc. Methods for treating skin infection by administering an il-4r antagonist
AU2015346150B2 (en) * 2014-11-14 2021-08-19 Regeneron Pharmaceuticals, Inc. Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
AU2017220184B2 (en) 2016-02-19 2024-04-18 Regeneron Pharmaceuticals, Inc. Methods for enhancing efficacy of a vaccine by administering an IL-4R antagonist
TWI728172B (zh) 2016-08-18 2021-05-21 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
HUE067888T2 (hu) 2016-09-01 2024-11-28 Regeneron Pharma Módszerek az allergia megelõzésére vagy kezelésére egy IL-4R antagonista adagolásával
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
EP4345110A3 (en) 2016-09-22 2024-06-12 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
MX2019009552A (es) 2017-02-17 2019-10-02 Hutchinson Fred Cancer Res Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios.
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
CA3079946A1 (en) 2017-10-30 2019-05-09 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
US11292847B2 (en) 2018-05-13 2022-04-05 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an IL-4R inhibitor
CA3132587A1 (en) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
WO2021026205A1 (en) 2019-08-05 2021-02-11 Regeneron Pharmaceuticals, Inc. Methods for treating atopic dermatitis by administering an il-4r antagonist
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
IL293487A (en) 2019-12-09 2022-08-01 Sanofi Biotechnology Methods for the treatment of digitally identified il-4/il-13-related disorders
MX2022011730A (es) 2020-03-27 2022-10-13 Regeneron Pharma Metodos para el tratamiento de dermatitis atopica mediante la administracion de un antagonista de il-4r.
EP4153300A1 (en) 2020-05-22 2023-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor
EP4274609A1 (en) 2021-01-08 2023-11-15 Regeneron Pharmaceuticals, Inc. Methods for treating peanut allergy and enhancing peanut allergen-specific immunotherapy by administering an il-4r antagonist

Also Published As

Publication number Publication date
UY32213A (es) 2010-05-31
CN106267190B (zh) 2021-01-26
EP2356151A1 (en) 2011-08-17
CL2009002004A1 (es) 2010-03-05
LUC00059I2 (2) 2018-03-28
LTC2356151I2 (lt) 2019-04-10
TW201919700A (zh) 2019-06-01
US20130078675A1 (en) 2013-03-28
IL211726A (en) 2015-10-29
EP3351560A1 (en) 2018-07-25
HUE066473T2 (hu) 2024-08-28
AU2009311496B9 (en) 2014-10-30
WO2010053751A1 (en) 2010-05-14
JP2012507294A (ja) 2012-03-29
LTPA2018002I1 (lt) 2018-02-12
US8735095B2 (en) 2014-05-27
DK3715372T3 (da) 2024-03-11
EP3715372B1 (en) 2024-01-24
JP6843208B2 (ja) 2021-03-17
PE20100738A1 (es) 2010-11-03
RS52782B (sr) 2013-10-31
SV2011003880A (es) 2011-08-15
FR18C1011I2 (fr) 2020-03-06
CN103739711A (zh) 2014-04-23
ES2802241T3 (es) 2021-01-18
AU2009311496B2 (en) 2014-05-29
CN103739711B (zh) 2016-09-14
ZA201101867B (en) 2012-08-29
JP7100731B2 (ja) 2022-07-13
JP2021087440A (ja) 2021-06-10
LT3715372T (lt) 2024-03-25
PL3064511T3 (pl) 2018-09-28
MY152448A (en) 2014-09-30
ES2404206T3 (es) 2013-05-24
PL3715372T3 (pl) 2024-06-24
PL3351560T3 (pl) 2020-09-21
HRP20240492T1 (hr) 2024-07-05
EP3715372A1 (en) 2020-09-30
BRPI0919853A2 (pt) 2016-03-15
SI3715372T1 (sl) 2024-05-31
TWI538686B (zh) 2016-06-21
ES2975006T3 (es) 2024-07-02
DK3064511T3 (en) 2018-07-16
JP2016041069A (ja) 2016-03-31
FR18C1011I1 (2) 2018-04-27
EP2636685A1 (en) 2013-09-11
PH12014500462A1 (en) 2015-06-01
TW201615216A (zh) 2016-05-01
DK2356151T3 (da) 2013-06-17
NZ591922A (en) 2012-03-30
JP6449125B2 (ja) 2019-01-09
PA8847001A1 (es) 2010-05-26
MX2011003346A (es) 2011-04-21
AR073978A1 (es) 2010-12-15
US12162943B2 (en) 2024-12-10
SI2356151T1 (sl) 2013-07-31
NL300922I2 (nl) 2019-01-15
EP4345111A3 (en) 2024-05-22
RS57522B1 (sr) 2018-10-31
US20100047254A1 (en) 2010-02-25
LUC00059I1 (2) 2018-01-03
RU2014147773A (ru) 2016-06-20
PT2356151E (pt) 2013-05-07
PT3064511T (pt) 2018-07-17
CN102197052B (zh) 2014-02-12
JP2024040526A (ja) 2024-03-25
PL2356151T3 (pl) 2013-08-30
TW201029664A (en) 2010-08-16
EP3064511A1 (en) 2016-09-07
ES2675917T3 (es) 2018-07-13
RU2663106C2 (ru) 2018-08-01
JP5844772B2 (ja) 2016-01-20
CY1114123T1 (el) 2016-07-27
JP6608505B2 (ja) 2019-11-20
RU2539774C3 (ru) 2020-11-06
HRP20181148T1 (hr) 2018-09-21
EP4345111A2 (en) 2024-04-03
CN106267190A (zh) 2017-01-04
IL211726A0 (en) 2011-06-30
FI3715372T3 (fi) 2024-03-18
TWI658833B (zh) 2019-05-11
EP2511300A2 (en) 2012-10-17
SMT201300074B (it) 2013-09-06
HUE039212T2 (hu) 2018-12-28
US20210163611A1 (en) 2021-06-03
JP2020007378A (ja) 2020-01-16
CY1122092T1 (el) 2020-07-31
JP2019055963A (ja) 2019-04-11
RS65385B1 (sr) 2024-04-30
BRPI0919853B8 (pt) 2021-05-25
US7608693B2 (en) 2009-10-27
US8075887B2 (en) 2011-12-13
JP2022160404A (ja) 2022-10-19
SMT201800362T1 (it) 2018-09-13
EP3351560B1 (en) 2020-04-22
US20180179288A1 (en) 2018-06-28
JO2865B1 (en) 2015-03-15
RU2011120194A (ru) 2012-12-10
AU2009311496A1 (en) 2010-05-14
NZ596093A (en) 2012-11-30
HK1159136A1 (en) 2012-07-27
CA2737044A1 (en) 2010-05-14
US20120052072A1 (en) 2012-03-01
UA102122C2 (ru) 2013-06-10
JP7824339B2 (ja) 2026-03-04
RU2539774C2 (ru) 2015-01-27
CY2018003I1 (el) 2018-09-05
EP2511300A3 (en) 2012-11-07
BRPI0919853B1 (pt) 2020-10-27
KR20110074980A (ko) 2011-07-05
CY2018003I2 (el) 2018-09-05
NO2023019I1 (no) 2023-05-02
SI3064511T1 (en) 2018-08-31
PT3351560T (pt) 2020-05-11
US20090074793A1 (en) 2009-03-19
KR101599706B1 (ko) 2016-03-04
HUS1800014I1 (hu) 2018-03-28
EP3064511B1 (en) 2018-04-18
HRP20130467T1 (en) 2013-06-30
PT3715372T (pt) 2024-03-14
CA2737044C (en) 2017-02-28
US8337839B2 (en) 2012-12-25
JP7442581B2 (ja) 2024-03-04
HK1250733A1 (en) 2019-01-11
LT3064511T (lt) 2018-07-10
JP5291802B2 (ja) 2013-09-18
ECSP11011010A (es) 2011-06-30
CR20110148A (es) 2011-04-27
MX356882B (es) 2018-06-19
MA32802B1 (fr) 2011-11-01
NO2018009I2 (no) 2019-01-30
CN102197052A (zh) 2011-09-21
NO2018009I1 (no) 2018-03-06
US20140271681A1 (en) 2014-09-18
NI201100064A (es) 2011-11-02
MX388436B (es) 2025-03-20
HN2011001210A (es) 2013-10-22
JP2013223495A (ja) 2013-10-31
DK3715372T5 (da) 2024-08-26
EP2356151B1 (en) 2013-04-10

Similar Documents

Publication Publication Date Title
CO6362024A2 (es) Anticuerpos humanos de alta afinidad para el receptor il-4 humano
AR083747A1 (es) Anticuerpos anti-il-23
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
PE20151289A1 (es) Anticuerpos que se unen al tl1a y sus usos
AR095980A1 (es) Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
SA112330988B1 (ar) أجسام مضادة تخص trop-2 واستخداماتها
TN2014000120A1 (en) Cd27l antigen binding proteins
CL2012002081A1 (es) Anticuerpo humanizado que se une a la cadena alfa del receptor de il-7 humano (cd127); proteina de enlace a antigeno que comprende una o mas regiones determinantes de complementariedad de dicho anticuerpo; molecula de acido nucleico que codifica una anticuerpo o proteina de enalce; vector de expresion, celula huesped recombinante; procedimiento para la produccion de una proteina de enlace a antigeno; procedimiento para tratar enfermedad autoinmune o inflamatoria.
MX2021003549A (es) Anticuerpos dobles especificos.
PE20150023A1 (es) Proteinas de union a antigeno st2
PE20150605A1 (es) Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
JP2013235610A5 (2)
MX373426B (es) Moleculas de enlace a il-18.
MX2010004910A (es) Anticuerpos monoclonales recombinantes y antigenos correspondientes para canceres colonico y pancreatico.
AU2015287227A8 (en) Immune-stimulating monoclonal antibodies against human interleukin-2
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
MX388698B (es) Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
CU20180129A7 (es) Anticuerpos anti-basigin humanizados
CO2017004753A2 (es) Anticuerpos que se unen a ccr6
CO2021014153A2 (es) Anticuerpo monoclonal que se une específicamente a gitr
PE20220004A1 (es) Anticuerpos monoclonales especificos para el antigeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por vrsh
PE20141683A1 (es) Anticuerpos monoclonales especificos para el antigeno m2-1 del virus respiratorio sincicial (vrs)
AR118355A1 (es) Métodos de fabricación para producir composiciones de anticuerpos anti-tnf

Legal Events

Date Code Title Description
FG Application granted